



FOR IMMEDIATE RELEASE

SUSTAINED NANO SYSTEMS TO PRESENT AT THE LIFE SCIENCE SUMMIT IN NEW YORK NOVEMBER 1-2, 2017

New York, NY – October, 10, 2017 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”) a privately-held biopharmaceutical company utilizing bio-resorbable nano and microparticles for long term drug delivery, will be featured in the Emerging Company Showcase of the Life Science Summit in New York City. SNS was selected based upon its “innovation in science and the quality of its management team.” The Company will report on the effectiveness of its Sustained Platform Technology to deliver extended duration of bioactive macromolecules, including long-term in-vivo results following the single administration of monoclonal antibodies. The SNS Platform Technology is a proprietary system designed to produce finely controlled sustained-release products based on fully scalable manufacturing processes.

The need to provide long term delivery of monoclonal antibodies and other large molecules will be essential for the conveyance of drugs in cases of cancer, retinal disease, and other chronic disease states. The SNS Platform Technology has the potential to satisfy this need, and provide a new therapeutic alternative to short term, multiple dosing of pharmaceutical agents.

“The results of our initial pilot study is a key step in reducing patient directed prescription directives. This one-time administered dose, designed to deliver drug from weeks to months, could help assure that full compliance is achieved without the inherent difficulties of long term patient self-medication,” said Dr. Barry Libin, President and Chief Executive Officer of SNS. “Currently, there is a significant gap in the care of chronic diseases where long term dosing is indicated.”

PROTEIN THERAPEUTICS

One of the many difficulties in the area of biotechnology is to achieve a technically viable methodology for long-term sustained delivery of proteins. This is often due to the observation that proteins can be easily hydrolyzed and denatured with short half-lives. Sustained Nano Particle technology has the potential to reduce these untoward affects, resulting in a steady longer-term protein release. This may include such important macromolecules as anti-angiogenic antibodies,

oligonucleotides, trans-gene expression products and growth factors, all of which have immense therapeutic value. For example, immunotherapy will play an important role in new cancer drugs, and monoclonal antibodies are presently being injected to the back of the eye, where serious visual impairment and blindness occur. The opportunity to reduce the frequency of drug dosing in diseases such as cancer, arthritis and macular degeneration (AMD), would be of great value.

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform technology is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that utilizes bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions, neurologic disorders, and dermatology. SNS may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support its research and development programs.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:
Dr. Barry Libin
[\(516\) 353-7983](tel:5163537983)
barlibin@gmail.com

Media Relations
info@newsfrontmedia.com

